Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Clinical Therapy and Diagnosis

Evaluation of 223Ra therapy on bone metastases of prostate cancer by 18F-fluoride PET/CT, 18F-FDG PET/CT and bone scintigraphy/SPECT

Katsuhiko Kato, Tetsuro Odagawa, Naotoshi Fujita, Yoshinori Tsutsumi, Shinji Abe, Seiichi Yamamoto and Shinji Naganawa
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 534;
Katsuhiko Kato
2Department of Radiological and Medical Laboratory Sciences Nagoya University Graduate School of Medicine Nagoya Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tetsuro Odagawa
2Department of Radiological and Medical Laboratory Sciences Nagoya University Graduate School of Medicine Nagoya Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naotoshi Fujita
2Department of Radiological and Medical Laboratory Sciences Nagoya University Graduate School of Medicine Nagoya Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshinori Tsutsumi
2Department of Radiological and Medical Laboratory Sciences Nagoya University Graduate School of Medicine Nagoya Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shinji Abe
3Nagoya University Hospital Nagoya Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Seiichi Yamamoto
2Department of Radiological and Medical Laboratory Sciences Nagoya University Graduate School of Medicine Nagoya Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shinji Naganawa
1Nagoya University Graduate School of Medicine Nagoya Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Article Information

vol. 60 no. supplement 1 534

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online May 21, 2019.

Copyright & Usage 
© 2019

Author Information

  1. Katsuhiko Kato2,
  2. Tetsuro Odagawa2,
  3. Naotoshi Fujita2,
  4. Yoshinori Tsutsumi2,
  5. Shinji Abe3,
  6. Seiichi Yamamoto2 and
  7. Shinji Naganawa1
  1. 1Nagoya University Graduate School of Medicine Nagoya Japan
  2. 2Department of Radiological and Medical Laboratory Sciences Nagoya University Graduate School of Medicine Nagoya Japan
  3. 3Nagoya University Hospital Nagoya Japan

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: May 2019 to April 2025

AbstractFullPdf
May 2019700
Jun 20193500
Jul 20192900
Aug 20191100
Sep 20193400
Oct 20191400
Nov 20192600
Dec 20191200
Jan 20202600
Feb 20201400
Mar 20203500
Apr 20202200
May 20202500
Jun 20201200
Jul 20201700
Aug 20203100
Sep 20205800
Oct 20204900
Nov 20203200
Dec 20203500
Jan 20212400
Feb 20212200
Mar 20211800
Apr 20212300
May 20212900
Jun 20212100
Jul 20213100
Aug 20216200
Sep 20213000
Oct 20214800
Nov 202110900
Dec 20217500
Jan 202211900
Feb 20223900
Mar 20223600
Apr 20223400
May 20223000
Jun 20221000
Jul 2022900
Aug 20221200
Sep 20221000
Oct 2022300
Nov 2022500
Dec 2022900
Jan 20231100
Feb 2023800
Mar 20231000
Apr 2023400
May 2023600
Jun 2023700
Jul 2023500
Aug 2023400
Sep 2023600
Oct 2023800
Nov 2023800
Dec 2023500
Jan 2024800
Feb 2024300
Mar 2024700
Apr 2024300
May 2024600
Jun 2024500
Jul 2024100
Aug 2024800
Sep 2024800
Oct 2024500
Nov 2024700
Dec 2024600
Jan 2025500
Feb 2025900
Mar 2025500
Apr 2025900
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 60, Issue supplement 1
May 1, 2019
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Evaluation of 223Ra therapy on bone metastases of prostate cancer by 18F-fluoride PET/CT, 18F-FDG PET/CT and bone scintigraphy/SPECT
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Evaluation of 223Ra therapy on bone metastases of prostate cancer by 18F-fluoride PET/CT, 18F-FDG PET/CT and bone scintigraphy/SPECT
Katsuhiko Kato, Tetsuro Odagawa, Naotoshi Fujita, Yoshinori Tsutsumi, Shinji Abe, Seiichi Yamamoto, Shinji Naganawa
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 534;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Evaluation of 223Ra therapy on bone metastases of prostate cancer by 18F-fluoride PET/CT, 18F-FDG PET/CT and bone scintigraphy/SPECT
Katsuhiko Kato, Tetsuro Odagawa, Naotoshi Fujita, Yoshinori Tsutsumi, Shinji Abe, Seiichi Yamamoto, Shinji Naganawa
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 534;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Clinical Therapy and Diagnosis

  • Added value of single photon emission computed tomography (SPECT) / Computed Tomography (CT) with radioiodine whole body scan in follow up of patients with differentiated thyroid cancer
  • The value of 18F-FDG PET / MR in skull-base bone invasion of nasopharyngeal carcinoma
  • Prognostic value of tumor metabolic imaging phenotype using FDG PET radiomics in HNSCC
Show more Oncology: Clinical Therapy and Diagnosis

Prostate Therapy II

  • Treatment of liver metastases of castration resistant prostate cancer with 177Lu-PSMA-617 and SIRT
  • Salivary gland toxicity after PRLT using Lu-177 PSMA in patients with advanced prostate cancer: A single-center systematic investigation
  • 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients with a single functioning kidney
Show more Prostate Therapy II

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire